Otsuka's delamanid reprieved by CHMP in double TB recommendation
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Otsuka's tuberculosis drug Deltyba (delanamid), which was turned down earlier this year in a previous recommendation. The committee has also given a positive opinion for Lucane Pharma's new formulation of Para-aminosalicylic acid as part of its ongoing efforts to tackle antibiotic resistance.